Leerink Partnrs Has Negative Outlook of JNJ Q4 Earnings

Johnson & Johnson (NYSE:JNJ - Free Report) - Investment analysts at Leerink Partnrs reduced their Q4 2025 earnings per share (EPS) estimates for shares of Johnson & Johnson in a report released on Wednesday, October 15th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $2.53 per share for the quarter, down from their previous forecast of $2.68. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 16th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Weiss Ratings raised Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Finally, Citigroup upped their price target on Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $199.59.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $191.79 on Friday. The company has a market cap of $461.90 billion, a price-to-earnings ratio of 18.51, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The stock has a 50 day simple moving average of $180.09 and a 200-day simple moving average of $164.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.

Institutional Investors Weigh In On Johnson & Johnson

Large investors have recently bought and sold shares of the stock. Apexium Financial LP grew its holdings in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB grew its holdings in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC grew its holdings in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its holdings in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after buying an additional 4,816 shares during the last quarter. Finally, Absher Wealth Management LLC grew its holdings in Johnson & Johnson by 1.2% during the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock valued at $35,752,000 after buying an additional 2,469 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.